Neumora Therapeutics (NMRA) Return on Equity [ROE] (2023 - 2026)
Neumora Therapeutics (NMRA) reported Return on Equity [ROE] of -369.36% for Q2 2026, down 246.76 percentage points from -122.60% a year earlier and down 114.53 percentage points from the prior quarter.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Return on Equity [ROE] (2023 - 2026) Analysis & Trends
For FY2025, Neumora Therapeutics posted Return on Equity [ROE] of -121.21%, down 56.73 percentage points from FY2024.
- By year, Return on Equity [ROE] came in at -64.48% in FY2024 (+2058.48 pp) and -2122.96% in FY2023.
- The Q2 2026 figure ranks as the lowest quarterly Return on Equity [ROE] in data going back to Q4 2023.
- Year over year, Return on Equity [ROE] has now declined in each of the last seven quarters, with an average year-over-year change of -102.55 percentage points over the last seven quarters.
- Per Business Quant data, the three quarters before Q2 2026 came in at -254.82% (Q1 2026), -200.76% (Q4 2025) and -150.01% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,165.98 Bn | 1,134.57 Bn | 19.71 Bn | 82.09% |
| 2 | Johnson & Johnson | 643.66 Bn | 563.53 Bn | 17.30 Bn | 19.33% |
| 3 | AbbVie | 500.95 Bn | 474.06 Bn | 12.70 Bn | - |
| 4 | Merck | 358.08 Bn | 312.45 Bn | 12.21 Bn | 7.21% |
| 5 | Novartis Ag | 301.84 Bn | 265.83 Bn | 11.24 Bn | 31.52% |
| 6 | Astrazeneca | 267.25 Bn | 240.94 Bn | 12.86 Bn | 21.39% |
| 7 | Amgen | 241.42 Bn | 196.81 Bn | 7.24 Bn | 83.75% |
| 8 | Gilead Sciences | 193.09 Bn | 167.28 Bn | 6.22 Bn | -18.38% |
| 9 | Pfizer | 171.63 Bn | 118.27 Bn | 10.94 Bn | 4.97% |
| 10 | Neumora Therapeutics | 72.92 Mn | -545.04 Mn | - | -369.36% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -369.36% |
| Mar 31, 2026 | -254.82% |
| Dec 31, 2025 | -200.76% |
| Sep 30, 2025 | -150.01% |
| Jun 30, 2025 | -122.60% |
| Mar 31, 2025 | -100.13% |
| Dec 31, 2024 | -80.22% |
| Sep 30, 2024 | -83.60% |
| Jun 30, 2024 | -67.98% |
| Mar 31, 2024 | -56.79% |
| Dec 31, 2023 | -48.73% |
API Access
Neumora Therapeutics Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=NMRA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "NMRA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=NMRA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();